anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objective: To investigate effectiveness of using empathy experience courses to guide the students who prior to occupational therapy(OT) practice in case-base clinical reasoning.

Materials and Methods: 30 students were recruited from 8 universities in Taiwan and randomly divided into an experimental group and a control group. The experimental group was given four 3-hour training sessions over 2 weeks, which included group instruction on empathy experience, clinical reasoning, and functional therapy case-oriented learning, while the control group was given case studies. Tests were administered before and after the series of sessions, including case report writing, C-JES-HPS, SACRR, and a follow-up visit at the end of the first phase of clinical practice using the C-JES-HPS and SACRR; course satisfaction surveys were completed after each session and at the follow-up visit to observe course satisfaction, usefulness, and recommendations. Data were analyzed using SPSS (version 20.0) with a significance level of 0.05. Univariate analyses with repeated measures 2-way analysis of variance were used to compare changes in empathy and clinical reasoning ability between the two groups of subjects and course satisfaction was presented as descriptive statistics. It was hypothesized that a case-oriented clinical reasoning training program using an empathy experience program would improve empathy and clinical reasoning skills in pre-practicum students in occupational therapy.
Increasing evidence from observational studies in hospitalized patients with and without diabetes indicates that hyperglycemia is a predictor of poor outcome. Blood glucose control with intensive insulin therapy in patients with acute critical illness reduces the risk of multiorgan failure and systemic infection, and decreases short- and long-term mortality.

The use of intravenous insulin infusion is the preferred route of insulin administration for the management of diabetic subjects with diabetic ketoacidosis and nonketotic hyperosmolar state, intraoperative and postoperative care, the postoperative period following heart surgery and organ transplantation, acute myocardial infarction, stroke, and critical care illness. Some of these settings may be characterized by, or associated with, severe or rapidly changing insulin requirements, generalized patient edema, impaired perfusion of subcutaneous sites, requirement for pressor support, and/or use of total parenteral nutrition. In these settings, the intravenous route for insulin administration has been considered superior than the subcutaneous injection of split-mixed regimen of intermediate and regular insulin with respect to rapidity of effect in controlling hyperglycemia, overall ability to achieve glycemic control, and most importantly, preventing hypoglycemic episodes. Recently, several insulin infusion protocols have been reported in the literature; these algorithms and formulas, however, may be confusing and difficult to follow and may increase the risk of dosing errors. To facilitate patients care, insulin algorithms could be placed on a computer and used at the patient bedside to direct the nursing staff administering the intravenous insulin. The Glucommander is one of such computer-derived insulin infusion protocol which has been used successfully in over 5,802 patients with diabetes between 1984 and 1998. The study hypothesizes that management of inpatient hyperglycemia with a computer-guided intravenous infusion protocol will facilitate smoother glycemic control with a lower rate of hypoglycemic events than treatment following a standard insulin infusion algorithm in critically ill patients in medical the ICU. The study also aims to determine differences in glycemic control between treatment with a computer-guided intravenous infusion protocol (Glucommander) and a standard insulin infusion algorithm in critically ill patients in the ICU.
BACKGROUND AND AIMS: Modern mass spectrometry imaging (MSI) enables single cells' metabolism exploration. Aims of this study were development of the single-cell MSI of human CD19+ lymphocytes and metabolic profiling of chronic lymphocytic leukemia (CLL).
MATERIALS AND METHODS: Blood donor (BD) samples were used for the optimization of CD19+ lymphocyte isolation and single-cell matrix-assisted laser desorption/ionization time-of-flight (MALDI TOF) MSI. Independent set of 200 CD19+ lymphocytes coming from 5 CLL patients and 5 BD was used for the CD19+ lymphocytes classification assessment and the untargeted metabolic profiling. CLL vs BD lymphocyte classification was performed using partial least squares-discriminant analysis (PLS-DA) using normalized single-cell mass spectra recorded in 300-600 and 600-950 Da ranges was applied.
RESULTS: Accuracy assessed by 10-fold cross-validation of CD19+ lymphocyte PLS-DA classification reached >90.0 %. Volcano plots showed 106 significantly altered m/z signals in CLL of which 9 were tentatively annotated. Among tentatively annotated m/z signals formaldehyde and glutathione metabolites and tetrahydrofolate stand out.
CONCLUSION: A method for single-cell MALDI TOF MSI of CD19+ lymphocytes was successfully developed. The method confirmed the significance of oxidative stress and single-carbon metabolism, pyruvate and fatty acid metabolism and apoptosis in CLL and it provided metabolic candidates for diagnostic applications.
The present invention relates to the use of azide-modified hyaluronic acid in drug delivery and/or drug storage. The azide-modified hyaluronic acid consists of the repeated disaccharides (. Beta., 1-4) -gluconic acid (GlcA) and (. Beta., 1-3) -azidoacetyl glucosamine (GlcNAz). The drug is DBCO modified drug. The invention discovers and proposes that the synthesized azide-modified hyaluronic acid is utilized for drug delivery and/or drug storage for the first time, and the azide-modified hyaluronic acid can be combined with DBCO modified drugs through click reaction, so that the purposes of drug delivery and/or drug storage are achieved. The azide-modified hyaluronic acid monomer or the azide-modified hyaluronic acid hydrogel is injected near the solid tumor, and after systemic doxorubicin prodrug DBCO-Dox is used, the azide-modified hyaluronic acid captures the doxorubicin prodrug DBCO-Dox, and after the azide-modified hyaluronic acid monomer or the azide-modified hyaluronic acid hydrogel is combined with the systemic doxorubicin prodrug DBCO-Dox, the doxorubicin prodrug DBCO-Dox is delivered to the focus, so that the medicine can be effectively activated, and the tumor progress can be relieved.
PROBLEM TO BE SOLVED: To provide a detergent composition containing a specific fatty acid glycol ester as a pearl gloss-imparting agent in or a detergent for the body or the hair. SOLUTION: This liquid detergent composition comprises the fatty acid glycol ester satisfying the following conditions (1) to (3). The condition (1): the fatty acid glycol ester is represented by general formula (I): R1 CO-(O-A)m -O- X [wherein R1 is an 12-22C alkyl group; A is C2 H4 or C3 H6 group; X is hydrogen atom or R1 CO group; m is 1-10]. The condition (2): the fatty acid glycol ester comprises a mono ester or a diester and contains the mono ester and the diester in a weight ratio of (0.01%:99.9%) to (10.0%:90.0%). The condition (3): The fatty acid of the fatty acid glycol ester comprises palmitic acid and stearic acid and contains the palmitic acid and stearic acid in a weight ratio of (80:20) to (40:60) and further, the fatty acid glycol ester is a dialkyl ester.  In the liquid detergent composition, the pearl gloss is stable for a long period to temporal influence and external factors such as temperature change in summer season or winter season.
Xanthohumol (XN) is a prominent prenylated flavonoid present in the hop plant (Humulus lupulus L.). Despite undoubted pro-healing properties of hop plant, there is still a need for clinical investigations confirming these effects as well as the underlying molecular mechanisms. The present study was designed to (1) establish the role of XN in non-invasive inflammation induced by chemical damage to zebrafish hair cells, (2) clarify if it influences cell injury severity, neutrophil migration, macrophage activation, cell regeneration, and (3) find out whether it modulates the gene expression profile of chosen immune and stress response markers. All experiments were performed on 3 dpf zebrafish larvae. After fertilization the embryos were transferred to appropriate XN solutions (0.1 μM, 0.3 μM and 0.5 μM). The 40 min 10 μM CuSO4 exposure evoked severe damage to posterior lateral line hair cells triggering a robust acute inflammatory response. Four readouts were selected as the indicators of XN role in the process of inflammation: 1) hair cell death, 2) neutrophil migration towards damaged hair cells, 3) macrophage activation and recruitment to damaged hair cells, 4) hair cell regeneration. The assessments involved in vivo confocal microscopy imaging and qPCR based molecular analysis. It was demonstrated that XN (1) influences death pathway of damaged hair cells by redirecting their severe necrotic phenotype into apoptotic one, (2) impacts the immune response via regulating neutrophil migration, macrophage recruitment and activation (3) modulates gene expression of immune system markers and (4) accelerates hair cell regeneration.
The invention provides a drug-loaded bacterial coating and a preparation method and application thereof, belonging to the technical field of microbial drugs. The drug-loaded bacterial coating disclosed by the invention overcomes the problem of insufficient treatment effect of microbial therapy in the prior art by carrying different drugs (including compound drugs and high-molecular biological agents). The drug-loaded bacterial coating provided by the invention has higher drug loading capacity, and meanwhile, the high drug encapsulation efficiency and the high drug loading capacity do not have obvious influence on the bacterial activity. The drug-loaded bacterial coating provided by the invention can also successfully load macromolecular biological products and can be used for multi-mode synergetic microbial therapy. The drug-loaded bacterial coating does not obviously affect the adhesive capacity of the drug-loaded bacterial coating, can better help bacterial colonization, and has better curative effect and higher biological safety. Can endow the bacteria with an editable treatment mode, and lays a foundation for preparing the next generation living bacteria biological preparation for advanced microbial treatment.
Patients ≥18 years old with suspected or known coronary artery disease who underwent CCTA will be included. CCTA images of subjects should be of good quality up to the DICOM 3.0 standards, obtained by CT scan with ≥64-slices. The subjects with unqualified CTA will be excluded. CCTA images will be analyzed in three methods (3 groups). Control group: CCTA images will be visually evaluated by physicians. Experiment group: CCTA images will be evaluated by physicians using RuiXin-CoronaryAI. Reference group: CCTA images will be visually evaluated by cardiologists with at least 10 years experiences, and the conclusions they offer will be used as golden standard. Primary outcomes are diagnostic sensitivity and specificity of RuiXin-CoronaryAI and coronary CTA for diagnosis of ischemia on a per-vessel basis. The effectiveness of RuiXin-CoronaryAI for diagnosis of coronary artery stenosis will be conducted by testing superiority of diagnostic sensitivity and non-inferiority of specificity.
Several natural products are being studied to identify new bioactive molecules with therapeutic potential for infections, immune modulation, and other pathologies. TLRs are a family of receptors that play a crucial role in the immune system, constituting the first line of immune defense. They recognize specific products derived from microorganisms that activate multiple pathways and transcription factors in target cells, which are vital for producing immune mediators. Mygalin is a synthetic acylpolyamine derived from hemocytes of the spider Acanthoscurria gomesiana. This molecule negatively regulates macrophage response to LPS stimulation by interacting with MD2 in the TLR4/MD2 complex. Here, we investigated the activity of Mygalin mediated by TLR2 agonists in cells treated with Pam3CSK4 (TLR2/1), Pam2CSK4, Zymosan (TLR2/6), and IFN-γ. Our data showed that Mygalin significantly inhibited stimulation with agonists and IFN-γ, reducing NO and IL-6 synthesis, regardless of the stimulation. There was also a significant reduction in the phosphorylation of proteins NF-κB p65 and STAT-1 in cells treated with Pam3CSK4. Molecular docking assays determined the molecular structure of Mygalin and agonists Pam3CSK4, Pam2CSK4, and Zymosan, as well as their interaction and free energy with the heterodimeric complexes TLR2/1 and TLR2/6. Mygalin interacted with the TLR1 and TLR2 dimer pathway through direct interaction with the agonists, and the ligand-binding domain was similar in both complexes. However, the binding of Mygalin was different from that of the agonists, since the interaction energy with the receptors was lower than with the agonists for their receptors. In conclusion, this study showed the great potential of Mygalin as a potent natural inhibitor of TLR2/1 and TLR2/6 and a suppressor of the inflammatory response induced by TLR2 agonists, in part due to its ability to interact with the heterodimeric complexes.
Phase separation regulates fundamental processes in gene expression and is mediated by the local concentration of proteins and nucleic acids, as well as nucleic acid secondary structures such as G-quadruplexes (G4s). These structures play fundamental roles in both host gene expression and in viral replication due to their peculiar localisation in regulatory sequences. Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is an episomal minichromosome whose persistence is at the basis of chronic infection. Identifying the mechanisms controlling its transcriptional activity is indispensable to develop new therapeutic strategies against chronic hepatitis B. The aim of this study was to determine whether G4s are formed in cccDNA and regulate viral replication. Combining biochemistry and functional studies, we demonstrate that cccDNA indeed contains ten G4s structures. Furthermore, mutations disrupting two G4s located in the enhancer I HBV regulatory region altered cccDNA transcription and viral replication. Finally, we showed for the first time that cccDNA undergoes phase separation in a G4-dependent manner to promote its transcription in infected hepatocytes. Altogether, our data give new insight in the transcriptional regulation of the HBV minichromosome that might pave the way for the identification of novel targets to destabilize or silence cccDNA.
Among the techniques used to overcome low vertical bone height in the maxilla is maxillary sinus floor augmentation. It can be performed either through a lateral window, or via a crestal access. Many long term studies and systematic reviews have showed that osteotome mediated sinus floor elevation (OSFE) technique is a highly predictable method for rehabilitation of patients with atrophied posterior maxilla with survival rates ranging from 92 % to 100 %. However, endoscopic studies have demonstrated the risk of membrane perforation while performing transalveolar sinus floor elevation. Moreover, the Summers technique can cause some complications as headache and paroxysmal positional vertigo. Additionally, the activity of osteotomes during the application of malleting pressure is difficult to control, resulting in unwanted instrument and/or graft penetration into the sinus cavity, potentially causing membrane penetration.

However, Huwais invented a new technology termed osseodensification for enhancing implant primary stability in 2015. This technology is performed with the use of specially developed drill bits (Densah burs) that combine the benefits of osteotomes with tactile control during the expansion. They have four or more lands with a negative rake angle, which prevents the bur's edges from cutting the bone and so compacts it smoothly. These drills have a tapered shank and a cutting chisel edge. They can thus go deeper into the osteotomy site, while the drill's gradually increasing diameter aids in the site's gradual enlargement. Drills are utilized to enter into the bone in a clockwise rotation (Cutting mode) until the appropriate depth of the osteotomy is reached. Afterwards, counterclockwise rotations (Densifying mode) generate a robust and dense layer of bone tissue along the osteotomy's walls and base. Through controlled deformation, this procedure burnishes bone along the inner layer of the osteotomy site. The goal is to construct a condensed layer of autografted bone along the implant's periphery and apex. This would improve the bone-implant contact, hence increasing insertion torque values and, as a result, implant primary stability.
All study subjects are to receive treatment with GentleMax Pro Plus device. Subjects will be scheduled to receive as little as one (1) and up to eight (8) treatments with the GentleMax Pro Plus™ Laser System. Up to 2 follow-ups will occur.
<P>PROBLEM TO BE SOLVED: To provide a melanogenesis inhibitor comprising a plant-derived component that suppresses the synthesis of melanin to cause pigmentation by stains, freckles, suntan etc., and is friendly to the skin, a cosmetic and an oral composition for melanogenesis inhibition.  <P>SOLUTION: The melanogenesis inhibitor comprises a seed extract of passion fruit as an active ingredient. Preferably the seed extract of passion fruit is extracted with hot water or ethanol-containing water. The cosmetic comprises the seed extract of passion fruit. The seed extract of passion fruit is made into a product as an oral composition for melanogenesis inhibition.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited.
Von Hippel-Lindau (VHL) disease is a rare genetic syndrome caused by a germline pathogenic variant in one VHL allele. Any somatic event disrupting the other allele induces VHL protein (pVHL) loss of function, ultimately leading to patients developing multiple tumours in multiple organs at multiple timepoints, and reducing life expectancy. Treatment of this complex, rare disease is often fragmented, as patients visit specialist clinicians in isolation at different medical centres. Consequently, patients can receive sub-optimal treatment that results in decreased quality of life and a poor experience of health care systems. In 2021, we established a comprehensive clinical centre at San Raffaele Hospital, Milan, devoted to VHL disease. The centre provides a structured programme for the diagnosis, surveillance and treatment of patients alongside research into VHL disease and involves a multidisciplinary team of dedicated physicians. This programme demonstrates the benefits of care centralization, including concentration of knowledge and services, synergy and multidisciplinary management, improved networking and patient resources, reducing health care costs, and fostering research and innovation. VHL disease provides an ideal model to assess the advantages of centralizing care for rare disease and represents an unparalleled opportunity to broaden our understanding of cancer biology in general.
A method for planning an examination of an examination object by a tomosynthesis machine includes: Raw data of the examination object are acquired from defined acquisition angles. An auxiliary data set is reconstructed from the raw data. Depth data are calculated based on the auxiliary data set calculating a number of projections from the perspective of a respectively defined projection center from the auxiliary data set or from the raw data. Each of the projections has a number of image points each linked with associated depth data. The projections are displayed and at least one projection is chosen. A position of an examination region of the examination object is marked therein. A real three-dimensional position of the examination region is calculated using the marked position and its depth data, and an examination path to the examination region is calculated.
Each capsule will contain 625 mg of Safflower oil. Participants will take 12 capsules per day over 6 months.
FIELD: medicine; pharmaceuticals.SUBSTANCE: present invention relates to a method of producing a porous orodispersible film, an orodispersible dry film. This method includes the following stages: i) preparing a suspension from a pharmaceutically acceptable solvent, a pharmaceutically acceptable matrix material and a pharmaceutically acceptable film-forming agent, wherein the solvent is selected such that the pharmaceutically acceptable matrix material is preferentially not dissolved therein, and the pharmaceutically acceptable film-forming material is dissolved therein; ii) dispensing the suspension onto a neutral substrate to form a wet film; and iii) drying the wet film to obtain a dry film. Proportion of the pharmaceutically acceptable film-forming agent in the total amount of the pharmaceutically acceptable matrix material and the film-forming agent is equal to 0.1–0.5 and the content of the solvent in terms of the total weight of the suspension in step i) is equal to 0.4–0.9. Orodispersible dry film has a dry layer thickness of 100 to 600 mcm. Theoretical film porosity is equal to 0.4–0.7. Film tensile strength is equal to 0.4–4 Nmm-2. Orodispersible dry film comprises, as components, a pharmaceutically acceptable matrix material and a pharmaceutically acceptable film-forming agent. Film has structure, according to which on one side it has solid surface, and its other side is porous.EFFECT: technical result is the development of orodispersible dry films, where one of the surfaces (on their upper side) is characterized by especially high porosity, which promotes absorption of biologically active substance applied on this side, while the opposite side of these films (their lower side) has a solid surface.19 cl, 1 tbl, 3 ex, 4 dwg
Autoimmune Diabetes Mellitus (AIDM) is a subtype of diabetes mellitus caused by autoimmune destruction of beta cells in the islet, including Type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA). Insulin has been used as a routine therapy for AIDM to alleviate the hyperglycemic status, yet cannot effectively prevent the progressing destruction of beta cells or preserve its function. Regulatory T cells expanded from umbilical cord blood (UCB-Treg) ex-vivo have shown strong capacity to control immune responses in autoimmune diseases, offering a hopeful therapeutic way for AIDM. Glucagon-like peptide (GLP-1) analog Liraglutide has been tested in large-scale clinical trial to prove its various benefits for beta cells and glucolipid metabolism in Type 2 diabetes and obesity patients. However, its clinical application in AIDM is not well-defined so far. The aim of this study is to investigate the potential use of Liraglutide with UCB-Treg infusion in AIDM and examine the safety and efficacy of this new therapy.
Patients will undergo scalp cooling via the Paxman Scalp Cooling device for the first 3 cycles of treatment. Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).